CARA News and Press, Cara Therapeutics Inc. From 03/28/22

STAMFORD, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from a sub-study of the KARE P...

Gainers: Tilray Brands (TLRY) +12%. Aurora Cannabis (ACB) +10%. Canopy Growth Corporation (CGC) +8%. Leafly Holdings (LFLY) +8%. Cronos Group  (CRON) +7%. Losers: The Honest Company (HNST) -20%. Purple Innovation (PRPL) -8%. Maxeon Solar Technologi...

I think the financial history here has been pretty bad. The company has only turned a profit in one of the past nine years. That said, investors in companies like this care far less about the past than the future, and the shares are reasonably priced in my view. Since this is a bi...

Flagging potential pricing issues for the company’s pruritus therapy, Korsuva, H.C. Wainwright has trimmed the price target of the commercial-stage biopharmaceutical company, Cara Therapeutics (NASDAQ:CARA) by nearly 14%. Vifor has partnered with Vifor to commercialize Korsuva for dial...

Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent ...

Gainers: Voyager Therapeutics (NASDAQ:VYGR) +22%. 908 Devices (NASDAQ:MASS) +16%. Viemed Healthcare (NASDAQ:VMD) +10%. Cara Therapeutics (NASDAQ:CARA) +9%. Neuronetics (NASDAQ:STIM) +9%. Losers: Alector (NASDAQ:ALEC) -19%. Can-Fite BioPharma (NYSE:CANF)...

Cara Therapeutics, Inc. (CARA) Q4 2021 Earnings Conference Call March 01, 2022, 16:30 ET Company Participants Iris Francesconi - Interim Head, Investor Relations Christopher Posner - President, CEO & Director Thomas Reilly - CFO Joana Goncalves - Chief Medical Officer Conference Call Part...

Shares of Cara Therapeutics (NASDAQ:CARA) are down 8% in after-hours trading after the company's Q4 2021 results missed on the top and bottom lines. In the quarter, the company swung to a net loss of $33.4M from net income of $78.9M in the year-ago period. Diluted EPS in the quarter...

Cara Therapeutics press release (NASDAQ:CARA): GAAP EPS of -$0.63 misses by $0.11. Revenue of $0.82M (-99.3% Y/Y) misses by $0.43M. Shares -5.5%. For further details see: Cara Therapeutics GAAP EPS of -$0.63 misses by $0.11, revenue of $0.82M misses by $0.43M

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic derma...